agilon health (NYSE:AGL) Price Target Cut to $5.00 by Analysts at Robert W. Baird

agilon health (NYSE:AGL) had its target price reduced by equities researchers at Robert W. Baird from $6.00 to $5.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “neutral” rating on the stock. Robert W. Baird’s target price would suggest a potential downside of 10.71% from the company’s previous close.

Other research analysts have also issued reports about the stock. Macquarie assumed coverage on shares of agilon health in a research note on Monday, December 16th. They set a “neutral” rating and a $3.00 target price on the stock. Needham & Company LLC reaffirmed a “hold” rating on shares of agilon health in a research report on Friday, March 21st. Sanford C. Bernstein raised agilon health from a “market perform” rating to an “outperform” rating and upped their price target for the stock from $3.30 to $8.50 in a research note on Tuesday, April 8th. Citigroup raised agilon health from a “sell” rating to a “neutral” rating and raised their price objective for the company from $1.75 to $2.25 in a research note on Friday, January 10th. Finally, Stifel Nicolaus increased their target price on agilon health from $2.00 to $3.00 and gave the stock a “hold” rating in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $4.29.

agilon health Trading Down 1.4 %

NYSE AGL opened at $5.60 on Tuesday. The stock has a market capitalization of $2.31 billion, a P/E ratio of -5.96 and a beta of 0.38. agilon health has a one year low of $1.50 and a one year high of $7.73. The business has a 50 day simple moving average of $4.03 and a 200 day simple moving average of $3.08. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.29 and a quick ratio of 1.29.

Institutional Investors Weigh In On agilon health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGL. Capital International Investors boosted its position in agilon health by 72.0% during the fourth quarter. Capital International Investors now owns 22,331,873 shares of the company’s stock worth $42,431,000 after purchasing an additional 9,346,295 shares during the period. Millennium Management LLC raised its position in shares of agilon health by 187.8% in the fourth quarter. Millennium Management LLC now owns 7,212,525 shares of the company’s stock valued at $13,704,000 after purchasing an additional 4,706,357 shares during the period. Algert Global LLC lifted its stake in shares of agilon health by 1,042.7% during the 4th quarter. Algert Global LLC now owns 2,108,687 shares of the company’s stock valued at $4,007,000 after buying an additional 1,924,157 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in agilon health by 49.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,541,549 shares of the company’s stock worth $8,629,000 after buying an additional 1,498,524 shares during the period. Finally, JPMorgan Chase & Co. grew its stake in agilon health by 326.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,415,419 shares of the company’s stock valued at $5,563,000 after buying an additional 1,083,492 shares in the last quarter.

agilon health Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.